# CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis

> **NCT02629419** · PHASE2 · COMPLETED · sponsor: **Matinas BioPharma Nanotechnologies, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Candidiasis, Chronic Mucocutaneous

## Interventions

- **DRUG:** Amphotericin B

## Key facts

- **NCT ID:** NCT02629419
- **Lead sponsor:** Matinas BioPharma Nanotechnologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-27
- **Primary completion:** 2021-11-09
- **Final completion:** 2022-08-06
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02629419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02629419, "CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02629419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*